MedTrace Logo

Complete Revascularization Via Inferior Part-sternotomy

NCT05835167 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2023-04-28

No results posted yet for this study

Summary

To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.

Conditions

  • Complete Revascularization
  • Coronary Artery Bypass Grafting
  • Multivessel Coronary Artery Disease

Interventions

PROCEDURE

Inferior part-sternotomy

A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.

PROCEDURE

Full median sternotomy

A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.

Sponsors & Collaborators

  • Tangshan Central Hospital

    collaborator OTHER

  • Baotou Central Hospital

    collaborator OTHER

  • Xiamen Second Hospital

    collaborator UNKNOWN

  • Beijing Shijitan Hospital, Capital Medical University

    collaborator OTHER

  • Peking University International Hospital

    collaborator OTHER

  • Shenzhen Sun Yat-sen Cardiovascular Hospital

    collaborator OTHER

  • Fuwai Yunnan Cardiovascular Hospital

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2025-05-04
Completion
2035-05-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05835167 on ClinicalTrials.gov